File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Tripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents

TitleTripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agents
Authors
KeywordsAnti-Inflammation
Anticancer
Celastrol
Nuclear Factor-Κb
Tripchlorolide
Tripterygium Wilfordii
Triptolide
Triptolide Derivatives
Issue Date2012
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEP
Citation
Clinical And Experimental Pharmacology And Physiology, 2012, v. 39 n. 3, p. 311-320 How to Cite?
Abstract1. Bioactive compounds from medicinal plants with anticancer and anti-inflammatory effects have become key resources in drug discovery fields for the treatment of various malignancies and immunological disorders. 2. Tripterygium wilfordii (TW) is a medicinal plant that exhibits profound immunosuppressive effects and has been used in herbal regimens for the treatment of immunological diseases for thousand years in China. 3. Procedures for the isolation and characterization of TW bioactive compounds have been well established. Over the past three decades, more than 46 diterpenoids, 20 new triterpenoids, 26 alkaloids and other small molecules have been identified from TW. 4. Triptolide, celastrol and tripchlorolide are among the bioactive compounds conferring the immunosuppressive and anticancer activities of TW. Accumulated evidence suggests that the TW bioactive compounds exert their pharmacological actions by modulating the transcriptional activity of nuclear factor-κB signalling molecule. 5. Triptolide derivatives with improved water solubility have emerged as promising drug candidates. Clinical trials are being conducted on the derivatives to provide encyclopaedic knowledge on triptolide pharmacokinetics in patients. © 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/173020
ISSN
2012 Impact Factor: 2.16
2015 SCImago Journal Rankings: 0.944
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, KFen_US
dc.contributor.authorYuan, Yen_US
dc.contributor.authorLuk, JMen_US
dc.date.accessioned2012-10-30T06:26:32Z-
dc.date.available2012-10-30T06:26:32Z-
dc.date.issued2012en_US
dc.identifier.citationClinical And Experimental Pharmacology And Physiology, 2012, v. 39 n. 3, p. 311-320en_US
dc.identifier.issn0305-1870en_US
dc.identifier.urihttp://hdl.handle.net/10722/173020-
dc.description.abstract1. Bioactive compounds from medicinal plants with anticancer and anti-inflammatory effects have become key resources in drug discovery fields for the treatment of various malignancies and immunological disorders. 2. Tripterygium wilfordii (TW) is a medicinal plant that exhibits profound immunosuppressive effects and has been used in herbal regimens for the treatment of immunological diseases for thousand years in China. 3. Procedures for the isolation and characterization of TW bioactive compounds have been well established. Over the past three decades, more than 46 diterpenoids, 20 new triterpenoids, 26 alkaloids and other small molecules have been identified from TW. 4. Triptolide, celastrol and tripchlorolide are among the bioactive compounds conferring the immunosuppressive and anticancer activities of TW. Accumulated evidence suggests that the TW bioactive compounds exert their pharmacological actions by modulating the transcriptional activity of nuclear factor-κB signalling molecule. 5. Triptolide derivatives with improved water solubility have emerged as promising drug candidates. Clinical trials are being conducted on the derivatives to provide encyclopaedic knowledge on triptolide pharmacokinetics in patients. © 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/CEPen_US
dc.relation.ispartofClinical and Experimental Pharmacology and Physiologyen_US
dc.subjectAnti-Inflammationen_US
dc.subjectAnticanceren_US
dc.subjectCelastrolen_US
dc.subjectNuclear Factor-Κben_US
dc.subjectTripchlorolideen_US
dc.subjectTripterygium Wilfordiien_US
dc.subjectTriptolideen_US
dc.subjectTriptolide Derivativesen_US
dc.titleTripterygium wilfordii bioactive compounds as anticancer and anti-inflammatory agentsen_US
dc.typeArticleen_US
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_US
dc.identifier.authorityLuk, JM=rp00349en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1440-1681.2011.05586.xen_US
dc.identifier.pmid21834865-
dc.identifier.scopuseid_2-s2.0-84857381128en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84857381128&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume39en_US
dc.identifier.issue3en_US
dc.identifier.spage311en_US
dc.identifier.epage320en_US
dc.identifier.isiWOS:000300689100013-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridWong, KF=49362744900en_US
dc.identifier.scopusauthoridYuan, Y=24438669200en_US
dc.identifier.scopusauthoridLuk, JM=7006777791en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats